



TML: CS: BDM-36/ 2020-21

11<sup>th</sup> November, 2020

Listing Department,  
**BSE Limited**,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Listing Department,  
**National Stock Exchange of India Ltd.**  
"Exchange Plaza",  
Bandra – Kurla Complex,  
Bandra – East, Mumbai- 400 051

Dear Sir/Madam,

**Sub: Outcome of the Board Meeting**

Meeting Commencement time : 11.15 A.M.  
Meeting Conclusion Time : 02.00 P.M.

The Board of Directors at its meeting held today, considered and approved the following matters:

1. Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30<sup>th</sup> September, 2020. A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and Half year ended 30<sup>th</sup> September, 2020 is enclosed herewith.

A copy of Unaudited Standalone and Consolidated Financial Results for the Quarter and half year ended 30<sup>th</sup> September, 2020 is enclosed herewith.

2. Appointment of Ms. Manjul Sandhu(DIN : 00330363) as an Additional Independent Woman Director

Disclosure pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 read with SEBI circular no CIR/CFD/CMD/4/2015 dated 09<sup>th</sup> September, 2015 is enclosed herewith.

We would like to further inform you that the Board of Directors had as per the requirement of SEBI circular no. LIST/COMP/14/2018-19 dated June 20, 2018 w.r.t. Enforcement of SEBI Orders regarding appointment of Directors by listed companies, verified that the said person is not debarred from holding the office of director pursuant to any SEBI order

This may be taken as compliance under the Listing Regulations.

Thanking you,

Yours faithfully

For **Themis Medicare Limited**.



**Sangameshwar Iyer**  
**Company Secretary & Compliance Officer**

**Themis Medicare Limited**

**Corporate Office:** 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

\*Tel.: 91-22-67607080 \*Fax: 91-22-67607070/ 28746621

**Regd. Office:** Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

**CIN No.:** L24110GJ1969PLC001590 \*Tel/ Fax No.: **Regd. Off.:** 0260-2431447/ 2430219

\*E-mail: themis@themismedicare.com \*Website: www.themismedicare.com



## ANNEXURE I

Disclosures pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 read with SEBI circular no CIR/CFD/CMD/4/2015 dated 09<sup>th</sup> September, 2015.

1. Ms. Manjul Sandhu

1.	<b>Reason for change</b>	:	Appointment of Ms. Manjul Sandhu(DIN : 00330363)as an Additional Independent Woman Director
2.	<b>Date of Appointment</b>	:	11 <sup>th</sup> November,2020
3.	<b>Brief Profile</b>	:	Ms. Manjul Sandhu is a B.com Graduate and has passed the Intermediate examination of the Chartered Accountancy course. She is well known as Business Woman and has more than 20 years experience in Business field. Besides, she has a good knowledge of Finance, Accounts and Audit.
4.	<b>Disclosure of relationships between directors</b> (in case of appointment of a director).	:	Not Applicable

For **Themis Medicare Limited.**



**Sangameshwar Iyer**  
**Company Secretary & Compliance Officer**

## Themis Medicare Limited

**Corporate Office:** 11/12 Udyog Nagar, S V Road, Goregaon (W), Mumbai – 400 104, India

\*Tel.: 91-22-67607080 \*Fax: 91-22-67607070/ 28746621

**Regd. Office:** Plot No. 69-A, G.I.D.C., Industrial Estate, Vapi-Gujarat

**CIN No.:** L24110GJ1969PLC001590 \*Tel/ Fax No.: **Regd. Off.:** 0260-2431447/ 2430219

\*E-mail: themis@themismedicare.com \*Website: www.themismedicare.com

**INDEPENDENT AUDITORS REVIEW REPORT ON THE QUARTERLY UNAUDITED STANDALONE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.**

**Review Report to  
The Board of Directors  
THEMIS MEDICARE LIMITED**

- 1. We have reviewed the 'accompanying statement of unaudited standalone financial results of **THEMIS MEDICARE LIMITED** (the "Company") for the quarter ended September 30, 2020 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015. As amended (the "Listing Regulations").*
- 2. This Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules Issued thereunder and other accounting principles generally accepted In India. Our responsibility is to express a conclusion on the Statement based on our review.*
- 3. We conducted our review of the Statement In accordance with the Standard on Review Engagements (SRE) 2410. "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" Issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of Interim financial Information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.*

4. *Based on our review conducted as above, nothing has come to our-attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, Including the manner in which It is to be disclosed, or that it contains any material misstatement.*

**For R.P. Sardar & Co.**  
**Chartered accountants**  
**(Firm's Registration No. 109273W)**

**RAJU PRABHUDEV**  
**SARDAR**

Digitally signed by RAJU PRABHUDEV SARDAR  
DN: c=IN, o=Personal,  
pseudonym=965a3e867235a15574663baa8af6268b1c9b85b794  
c1b30e52a12b87bc510402, postalCode=400103,  
st=MAHARASHTRA,  
serialNumber=7eacd4d3dba09e46363cda21c487ae9ae0d6da59  
7473b6f5625b43c2aa18f0, cn=RAJU PRABHUDEV SARDAR  
Date: 2020.11.11 13:45:43 +05'30'

**Raju P. Sardar**  
**(Proprietor)**

**(Membership No. 037845)**

**Place: Mumbai**

**Date: 11<sup>th</sup> November, 2020**

**UDIN : 20037845AAAAJW2571**

**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED.**

*Review Report to  
The Board of Directors  
**THEMIS MEDICARE LIMITED***

- 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **THEMIS MEDICARE LIMITED** (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its joint ventures for the quarter ended September 30, 2020 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").*
- 2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review*
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.*

*We also performed procedures in accordance with the Circular No. CIR/CFD/CMD 1/44/2019 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.*

4. *The Statement includes the results of the following entities:*

**Subsidiaries**

- a. *Carpo Medical Limited (UK)*
- b. *Themis lifestyle Private limited*
- c. *Artemis biotech Limited*

**Associates**

- a. *Gujarat Themis Biosys Limited*
- b. *Long Island Nutritionals Private Limited*

**Associate (Joint Venture)**

- a. *Richter Themis Medicare (India) Private Limited*

5. *Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Has not disclosed the information required to be disclosed in terms of the Listing Regulations including the manner in which it is to be disclosed or that it contains any material misstatement.*
6. *The Statement includes the interim financial results of 2 Associates & 1 Joint Venture which have not been reviewed, whose interim financial results reflect total revenues of Rs.9,354.73 Lakhs, total net Profit after tax of Rs.2,220.46 Lakh and total comprehensive income of Rs. 0.05 Lakh for the quarter ended 30 September, 2020, as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.*

*One subsidiary which is located outside India whose financial statements and other financial information have been prepared in accordance with accounting principles, generally accepted in the country and which have been audited by other auditor under generally accepted auditing standards applicable in the country. The Company's management has converted the financial statement of such subsidiary located outside*

*India from accounting principles generally accepted in its country to accounting principles generally accepted in India. We have audited these conversion adjustments made by the Company's management. Our opinion in so far as it relates to the balances and affair of such subsidiary located outside India is based on the report of the other auditor and the conversion adjustments prepared by the management of the Company and audited by us.*

*Our conclusion on the Statement is not modified in respect of the above matter.*

**For R.P. Sardar & Co.  
Chartered accountants  
(Firm's Registration No.-109273W)**

**RAJU PRABHUDEV  
SARDAR**

Digitally signed by RAJU PRABHUDEV SARDAR  
DN: c=IN, o=Personal,  
pseudonym=9a5a3e8e7235a15574663baa8afc368b1c9b85b  
794c1b38a52a12899fbc510402, postalCode=400103,  
st=MAHARASHTRA,  
serialNumber=7eaccad3dbae09e46363da21c487ae9ae0d6da  
597f4753565625b43c2aa18f0, cn=RAJU PRABHUDEV SARDAR  
Date: 2020.11.11 13:43:27 +05'30'

**Raju P. Sardar  
(Proprietor)**

**(Membership No. 037845)**

**Place:** Mumbai

**Date:** 11<sup>th</sup> November, 2020

**UDIN : 20037845AAAAJX2791**

# THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.

Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

## Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2020.

( Amount in INR Lakhs )

	Particulars	STANDALONE					
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended	Previous year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019	31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Revenue from Operations	5,489.23	4,848.84	5,032.30	10,338.07	10,165.67	20,158.83
2	Other Income	213.11	35.90	7.75	249.01	17.82	347.12
3	Total Income ( 1 + 2 )	5,702.34	4,884.74	5,040.05	10,587.08	10,183.49	20,505.95
4	Expenses :						
	(a) Cost of materials consumed	1,904.53	1,249.21	1,323.28	3,153.74	2,617.55	5,137.60
	(b) Purchases of stock-in-trade	275.30	255.69	509.58	530.99	998.07	1,529.86
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(355.21)	187.09	36.18	(168.12)	31.79	(349.16)
	(d) Employee benefits expense	953.83	1,016.19	1,127.79	1,970.02	2,209.98	4,427.51
	(e) Finance Costs	370.75	299.46	330.47	670.21	651.48	1,287.96
	(f) Depreciation and amortisation expense	203.97	203.82	206.26	407.79	412.78	826.81
	(g) Other expenses	1,738.88	910.81	1,492.00	2,649.69	3,014.04	5,844.87
	Total expenses	5,092.05	4,122.27	5,025.56	9,214.32	9,935.69	18,705.45
5	Profit / (Loss) before exceptional items and tax (3 - 4)	610.29	762.47	14.49	1,372.76	247.80	1,800.50
6	Exceptional items	-	-	-	-	-	-
7	Profit / (Loss) before tax (5 - 6)	610.29	762.47	14.49	1,372.76	247.80	1,800.50
8	Tax expense :						
	(a) Current Tax	-	-	-	-	-	-
	(b) Deferred Tax	41.96	198.11	(48.96)	240.07	(69.07)	209.30
9	Profit / (Loss) for the period (7 - 8)	568.33	564.36	63.45	1,132.69	316.87	1,591.20
10	Other Comprehensive Income :						
	(a i) Items that will not be reclassified to Profit & Loss	(2.79)	(2.79)	(1.83)	(5.58)	(3.67)	(11.17)
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	0.71	0.70	0.54	1.41	1.07	2.81
	(b) Items that will be reclassified to Profit & Loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9 + 10)	566.25	562.27	62.16	1,128.52	314.27	1,582.84
12	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	918.85	918.80	918.09	918.85	918.09	918.80
13	Other Equity (Excluding Revaluation Reserve)						11,515.40
14	Earnings per share :						
	(a) Basic	6.19	6.14	0.69	12.33	3.45	17.32
	(b) Diluted	6.18	6.14	0.69	12.32	3.45	17.32





# THEMIS MEDICARE LTD

CIN NO : L24110GJ1969PLC001590

Regd. Off. Plot No. 69A, GIDC Indl. Estate, Vapi - 396195, Dist Valsad, Gujarat. (T) 0260-2431447 / 0260-2430219.


Corporate Office : 11/12, Udyog Nagar, S. V. Road, Goregaon (West), Mumbai-400 104.

Email ID : themis@themismedicare.com. Website Address : www.themismedicare.com.

## Statement of Unaudited Financial Results for the quarter and half year ended 30th September 2020.

( Amount in INR Lakhs )

	Particulars	CONSOLIDATED						
		3 months ended	Preceeding 3 months ended	Corresponding 3 months ended	Year to date figures for the current period ended	Year to date figures for the previous period ended		Previous year ended
		30/09/2020	30/06/2020	30/09/2019	30/09/2020	30/09/2019		31/03/2020
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)		
1	Revenue from Operations	5,489.23	4,848.84	5,032.30	10,338.07	10,165.67	20,158.83	
2	Other Income	213.11	35.90	7.75	249.01	17.19	346.49	
3	Total Income ( 1 + 2 )	5,702.34	4,884.74	5,040.05	10,587.08	10,182.86	20,505.32	
4	Expenses :							
	(a) Cost of materials consumed	1,904.53	1,249.21	1,323.28	3,153.74	2,617.55	5,137.60	
	(b) Purchases of stock-in-trade	275.30	255.69	509.58	530.99	998.07	1,529.86	
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(355.21)	187.09	36.18	(168.12)	31.79	(349.16)	
	(d) Employee benefits expense	953.83	1,016.19	1,127.79	1,970.02	2,209.98	4,427.51	
	(e) Finance Costs	370.75	299.48	330.49	670.23	651.51	1,288.04	
	(f) Depreciation and amortisation expense	203.97	203.82	206.26	407.79	412.84	827.20	
	(g) Other expenses	1,741.02	911.14	1,492.34	2,652.16	3,014.38	5,847.35	
	Total expenses	5,094.19	4,122.62	5,025.92	9,216.81	9,936.12	18,708.40	
5	Profit / (Loss) before exceptional items, share of Profit/(Loss) of associates and joint venture and tax (3 - 4)	608.15	762.12	14.13	1,370.27	246.74	1,796.92	
6	Exceptional items	-	-	-	-	-	-	
7	Profit / (Loss) before share of Profit / (Loss) of associates and joint venture and tax (5 - 6)	608.15	762.12	14.13	1,370.27	246.74	1,796.92	
8	Add: Share of Profit / (Loss) of associates and a joint venture for the period	247.26	211.27	104.74	458.53	367.88	890.54	
9	Profit / (Loss) before tax (7 + 8)	855.41	973.39	118.87	1,828.80	614.62	2,687.46	
10	Tax expense :							
	(a) Current Tax	-	-	-	-	-	-	
	(b) Deferred Tax	41.96	198.11	(48.96)	240.07	(69.07)	209.30	
11	Profit / (Loss) for the period (9 - 10)	813.45	775.28	167.83	1,588.73	683.69	2,478.16	
	Attributable to :							
	Equity holders of the Parent	813.45	775.28	167.83	1,588.73	683.69	2,478.17	
	Non - Controlling interests	-	-	-	-	-	(0.01)	
12	Other Comprehensive Income :							
	(a i) Items that will not be reclassified to Profit & Loss	(2.79)	(2.79)	(1.83)	(5.58)	(3.67)	(11.17)	
	(a ii) Income Tax relating to Items that will not be reclassified to Profit & Loss	0.71	0.70	0.54	1.41	1.07	2.81	
	(b i) Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method	(0.00)	0.01	0.02	0.01	0.01	0.02	
	(b) Items that will be reclassified to Profit & Loss	1.34	5.94	(6.01)	7.28	(2.35)	1.21	
13	Total Comprehensive Income for the period (11 + 12)	812.71	779.14	160.55	1,591.85	678.75	2,471.03	
	Attributable to :							
	Equity holders of the Parent	812.71	779.14	160.55	1,591.85	678.75	2,471.04	
	Non - Controlling interests	-	-	-	-	-	(0.01)	
14	Paid up Equity Share Capital (Face Value of Rs.10/- per Equity Share)	918.85	918.80	918.09	918.85	918.09	918.80	
15	Other Equity (Excluding Revaluation Reserve)							
16	Earnings per share :						13,886.44	
	(a) Basic	8.85	8.44	1.83	17.29	7.45	26.97	
	(b) Diluted	8.85	8.44	1.83	17.28	7.45	26.97	



# THEMIS MEDICARE LTD

## NOTES :

### 1 Statement of Assets and Liabilities :

( Amount in INR Lakhs )

	( STANDALONE )		( CONSOLIDATED )	
	As at 30th September, 2020	As at 31st March, 2020	As at 30th September, 2020	As at 31st March, 2020
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<b>ASSETS</b>				
<b>Non-Current Assets</b>				
(a) Property, Plant and Equipment	11,185.82	11,488.08	11,186.45	11,488.71
(b) Capital Work-in-Progress	1,484.06	753.69	1,484.06	753.69
(c) Intangible Assets	131.64	142.56	131.64	142.56
(d) Investments accounted for using the equity method	-	-	3,988.61	3,529.45
(e) Financial Assets				
(i) Investments	1,094.77	1,095.93	16.62	17.78
(ii) Other Financial Assets	27.68	30.74	27.68	30.74
(f) Deferred Tax Asset (Net)	218.57	457.24	218.57	457.24
(g) Other Non-Current Assets	509.45	522.04	509.45	522.04
	<b>14,651.99</b>	<b>14,490.28</b>	<b>17,563.08</b>	<b>16,942.21</b>
<b>Current assets</b>				
(a) Inventories	5,586.97	5,424.28	5,616.87	5,460.89
(b) Financial Assets				
(i) Investments				
(i) Trade Receivables	9,257.35	10,283.79	9,221.99	10,248.44
(ii) Cash and Cash Equivalents	831.07	332.81	835.87	334.15
(iii) Bank Balances Other than (ii) above	321.85	195.33	321.85	195.33
(iv) Other Financial Assets	487.46	485.37	487.46	485.37
(c) Other Current Assets	1,651.84	1,406.10	1,568.63	1,324.95
	<b>18,136.54</b>	<b>18,127.68</b>	<b>18,052.67</b>	<b>18,049.13</b>
<b>TOTAL</b>	<b>32,788.53</b>	<b>32,617.96</b>	<b>35,615.75</b>	<b>34,991.34</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Equity</b>				
(a) Equity Share capital	918.85	918.80	918.85	918.80
(b) Other Equity	15,981.85	15,012.62	18,803.28	17,383.65
<b>Equity attributable to equity holders of the parent</b>	<b>16,900.70</b>	<b>15,931.42</b>	<b>19,722.13</b>	<b>18,302.45</b>
Non Controlling Interest	-	-	(0.05)	(0.05)
<b>Total Equity</b>	<b>16,900.70</b>	<b>15,931.42</b>	<b>19,722.08</b>	<b>18,302.40</b>
<b>Liabilities</b>				
<b>Non Current Liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	2,118.49	1,185.45	2,118.49	1,185.45
(ii) Other Financial Liabilities	5.07	22.47	5.07	22.47
(b) Provisions	-	-	-	-
	<b>2,123.56</b>	<b>1,207.92</b>	<b>2,123.56</b>	<b>1,207.92</b>
<b>Current Liabilities</b>				
(a) Financial Liabilities				
(i) Borrowings	6,244.06	7,661.33	6,244.06	7,661.33
(ii) Trade Payables				
total outstanding dues of micro enterprises and small enterprises	37.50	109.49	37.50	109.49
total outstanding dues of creditors other than micro enterprises and small enterprises	3,754.00	2,858.48	3,754.32	2,858.82
(iii) Other Financial Liabilities	3,496.89	4,655.61	3,501.05	4,656.31
(b) Other Current Liabilities	68.67	27.88	70.03	29.24
(c) Provisions	163.15	165.83	163.15	165.83
	<b>13,764.27</b>	<b>15,478.62</b>	<b>13,770.11</b>	<b>15,481.02</b>
<b>TOTAL</b>	<b>32,788.53</b>	<b>32,617.96</b>	<b>35,615.75</b>	<b>34,991.34</b>



# THEMIS MEDICARE LTD

## 2 Statement of Cash Flows :

( Amount in INR Lakhs )

Particulars	( STANDALONE )		( CONSOLIDATED )	
	As at 30th September, 2020	As at 30th September, 2019	As at 30th September, 2020	As at 30th September, 2019
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>				
Profit before tax	1,372.76	247.80	1,828.80	614.59
Adjustments for:				
Depreciation and amortisation expense	407.79	412.78	407.79	412.85
Loss on sale of property, plant and equipment	(1.33)	1.07	(1.33)	1.07
Employee share-based payment expense	-	2.76	-	2.76
Changes in fair value of financial instruments at fair value through profit or loss	1.15	3.43	1.15	3.43
Fair valuation of financial guarantee	-	(0.63)	-	-
Dividend and interest income classified as investing cash flows	(205.37)	(15.38)	(205.37)	(15.38)
Finance costs	601.24	651.48	601.24	651.51
Reversal of loss allowance on financial assets	-	-	-	-
Share of (profit) Loss from joint ventures and associates	-	-	(458.54)	(367.89)
<b>Change in operating assets and liabilities:</b>				
(Increase)/Decrease in trade receivables	1,026.44	(805.28)	1,026.44	(840.64)
(Increase)/Decrease in inventories	(162.69)	222.87	(163.33)	216.89
Increase/(decrease) in trade payables	823.53	(11.07)	823.51	22.63
(Increase)/Decrease in other financial assets	0.97	(160.70)	0.97	(160.70)
(Increase)/decrease in other assets	(245.74)	128.14	(243.67)	128.42
Increase/(decrease) in provisions	(8.26)	19.64	(7.15)	23.31
(Increase)/Decrease in Other bank balance	(126.52)	(34.85)	(126.52)	(34.86)
Increase/(decrease) in other financial liabilities	(401.17)	66.21	(397.73)	69.33
Increase/(decrease) in other liabilities	26.90	(181.53)	26.90	(182.24)
<b>Cash generated from operations</b>	<b>3,109.70</b>	<b>546.74</b>	<b>3,113.16</b>	<b>545.08</b>
Less: (Income taxes paid)/ refund received (Net)	12.59	(12.65)	12.59	(12.65)
<b>Net cash inflow from operating activities</b>	<b>3,122.29</b>	<b>534.09</b>	<b>3,125.75</b>	<b>532.43</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>				
Payments for property, plant and equipment	(827.26)	(93.03)	(827.26)	(93.03)
Proceeds from sale of property, plant and equipment	3.61	3.15	3.61	3.15
Dividends received	192.80	0.00	192.80	-
Interest received	12.57	15.38	12.57	15.38
<b>Net cash outflow from investing activities</b>	<b>(618.28)</b>	<b>(74.50)</b>	<b>(618.28)</b>	<b>(74.50)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>				
Proceeds from issues of equity shares	1.55	-	1.55	-
Proceeds from current borrowings (Net)	(1,417.27)	281.63	(1,417.27)	281.61
Receipts / Repayment of non Current borrowings	28.53	39.63	28.53	39.63
Repayment of lease liabilities	(17.32)	-	(17.32)	-
Interest paid	(601.24)	(651.48)	(601.24)	(651.51)
<b>Net cash inflow (outflow) from financing activities</b>	<b>(2,005.75)</b>	<b>(330.22)</b>	<b>(2,005.75)</b>	<b>(330.27)</b>
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>498.26</b>	<b>129.37</b>	<b>501.72</b>	<b>127.66</b>
Cash and Cash Equivalents at the beginning of the financial year	332.81	172.86	334.15	175.47
<b>Cash and Cash Equivalents at end of the year</b>	<b>831.07</b>	<b>302.23</b>	<b>835.87</b>	<b>303.13</b>
<b>Reconciliation of cash and cash equivalents as per the cash flow statement:</b>				
Cash and cash equivalents as per above comprise of the following:				
Balances with banks				
- On current accounts	824.91	284.23	829.45	284.87
Cash on hand	6.16	18.00	6.42	18.26
<b>Balances per statement of cash flows</b>	<b>831.07</b>	<b>302.23</b>	<b>835.87</b>	<b>303.13</b>



## THEMIS MEDICARE LTD

- 3) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its meeting held on November 11, 2020.
- 4) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016.
- 5) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments".
- 6) The COVID pandemic is unprecedented and has affected the operations as well as results of the Company. The manufacturing facility of the Company which was shut down in the last week of March 2020 due to country wide lockdown, resumed operations in a phased manner from the first week April, 2020 after receiving requisite approvals. The Company has taken adequate precautions for safety and well-being of the employees while resumption of operations of its plant. The Company has taken into consideration the impact of the known internal and external events arising from COVID - 19 pandemic while preparing the financial information and have considered the possible effects on the carrying amounts of trade receivables and inventories. However, the impact assessment of COVID - 19 is an on-going process, given the uncertainties associated with its nature and duration, hence the same may differ from that estimated as at the date of approval of these financial results. The Company will continue to closely monitor any material changes to future economic conditions and the consequent impact on its business, if any.
- 7) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable.

By Order of the Board  
For THEMIS MEDICARE LTD



Dr. SACHIN PATEL  
(Managing Director & CEO )  
(DIN No. 00033353 )

Place : Mumbai  
Date : 11th November, 2020